Shattuck Labs

Update in progress

STTK (NasdaqGS)

Company RatingNeutral
SectorHealthcare
IndustryBiotechnology

Shattuck Labs is a clinical-stage biotechnology company focused on antibodies for inflammatory and immune-mediated diseases. It develops SL-325, a DR3-blocking monoclonal antibody in Phase I for TNF-like ligand 1A, and SL-425, a longer-half-life version in IND-enabling toxicity studies. The company also pursues preclinical DR3-based bispecifics for inflammatory bowel disease and other indications, plus the TRIM7 oncology program. Founded 2016, based in Austin, Texas.

Company score

Sentiment: 0.25; SentimentMeasures the overall tone of recent coverage and discussion about the company.−10 negative · 0 neutral · +10 positive
Environment: 0.00; EnvironmentAssesses the company’s environmental impact, risks, and sustainability practices.−10 negative · 0 neutral · +10 positive
Social: 0.15; SocialAssesses the company’s influence on employees, customers, communities, and wider society.−10 negative · 0 neutral · +10 positive
Governance: 0.07; GovernanceAssesses leadership, accountability, transparency, and business ethics.−10 negative · 0 neutral · +10 positive
Sustainability: 0.06; SustainabilityCombines environmental, social, and governance signals into an overall sustainability score.−10 negative · 0 neutral · +10 positive
Impact Score: 0.15; Impact ScoreCombines sentiment and sustainability performance into an assessment of the company’s overall impact.−10 negative · 0 neutral · +10 positive